Market research
YPH.F Astellas Pharma Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 23B
- P/E ratio
- 14.6
- Analyst target
- Not available
- Dividend yield
- 3.4%
- Beta
- 0.08
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- JP3942400007
- Market cap
- 23B
- P/E ratio
- 14.6
- Analyst target
- Not available
- Dividend yield
- 3.4%
- Beta
- 0.08
About
About Astellas Pharma Inc
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the YPH.F discussion.
5 years, 5 months ago
Astellas Pharma Inc is currently in a long term uptrend where the price is trading 31.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.5.
Astellas Pharma Inc's total revenue sank by 3.7% to $325B since the same quarter in the previous year.
Its net income has dropped by 2.3% to $60B since the same quarter in the previous year.
Finally, its free cash flow grew by 127.8% to $101B since the same quarter in the previous year.
Based on the above factors, Astellas Pharma Inc gets an overall score of 3/5.